Exploring the Prognostic Role of Ki67 Proliferative Index in Merkel Cell Carcinoma of the Skin: Clinico-Pathologic Analysis of 84 Cases and Review of the Literature

Stefano La Rosa 1,2 · Matteo Bonzini 3 · Amedeo Sciarra 4 · Sofia Asioli 5 · Roberta Maragliano 6 · Martina Arrigo 7 · Maria Pia Foschini 5 · Alberto Righi 8 · Francesca Maletta 9 · Alberico Motoles 7 · Mauro Papotti 9 · Fausto Sessa 6 · Silvia Uccella 6

Accepted: 10 July 2020 / Published online: 22 July 2020 © The Author(s) 2020

Abstract
The exact prediction of outcome of patients with Merkel cell carcinoma (MCC) of the skin is difficult to determine, although several attempts have been made to identify clinico-pathologic prognostic factors. The Ki67 proliferative index is a well-known marker routinely used to define the prognosis of patients with neuroendocrine neoplasms. However, its prognostic value has been poorly investigated in MCC, and available published results are often contradictory mainly because restricted to small series in the absence of standardized methods for Ki67 evaluation. For this reason, we explored the potential prognostic role of Ki67 proliferative index in a large series of MCCs using the WHO standardized method of counting positive cells in at least 500 tumor cells in hot spot areas on camera-captured printed images. In addition, since MCC may be considered as the cutaneous counterpart of digestive neuroendocrine carcinomas (NECs), we decided to stratify MCCs using the available and efficient Ki67 threshold of 55%, which was found prognostic in digestive NECs. This choice was also supported by the Youden index analysis. In addition, we analyzed the prognostic value of other clinico-pathologic parameters using both univariate and multivariate analysis. Ki67 index appeared significantly associated with prognosis at univariate analysis together with stage IV, lack of MCPyV, and p63 expression, but not at the multivariate analysis, where survival resulted independently influenced by p63 expression and tumor stage, only.

Keywords Merkel cell carcinoma · Ki67 standardized count · Prognosis · Overall survival · Disease-specific survival

Introduction
Merkel cell carcinoma (MCC) is a rare neuroendocrine carcinoma of the skin, but its incidence has largely increased over the last 20 years, probably depending on the increasing effects of risk factors such as advanced age, UV exposure, and systemic immunosuppression [1]. The reported annual incidence varies between 0.1 and 0.88 per 100,000 people, with differ-
ences among geographical regions: higher rates have been observed in Australia and New Zealand and the lowest in Eastern France and Scotland [2]. MCC is more frequently observed in elderly white male patients (mean age at diagnosis of 73.6 years), although younger patients, mostly if immunosuppressed due to organ transplantation, can also be affected. MCC incidence is also increased in patients with other malignancies including melanoma, multiple myeloma, and non-Hodgkin lymphoma, especially chronic lymphocytic leukemia [2].

MCC is an aggressive cancer, and several attempts have been made to identify clinico-pathologic factors useful to stratify patients in different prognostic categories. From an etiological point of view, MCC can be divided into two main groups with apparent different behaviors on the basis of the presence or absence of an associated infection by Merkel cell polyomavirus (MCPyV). MCC unassociated with MCPyV infection seems to show a worse prognosis [3]. However, although several prognostic markers have been proposed, the exact prediction of the individual outcome remains difficult to be determined.

Ki67 proliferative index is a well-known prognostic marker for both well-differentiated neuroendocrine tumors (NETs) and poorly differentiated neuroendocrine carcinomas (NECs) of the digestive system, and is currently routinely evaluated in their diagnostic work-up [4]. Although its prognostic value has also been recognized in other neuroendocrine neoplasms (NENs), such as those located in the pituitary, parathyroid, and lung [5–8], Ki67 proliferative index has been poorly investigated in cutaneous MCC; thus, its role remains to be clarified.

In the present retrospective study, we explored the prognostic role of Ki67 proliferative index in a large series of MCCs integrating our results with literature findings. In addition, we investigated other potential clinico-pathologic prognosticators, with the aim to identify useful parameters to stratify MCC patients in different risk categories.

Materials and Methods

Cases

The surgical pathology databases of the Units of Pathology of the ASST Sette Laghi/University of Insubria (Varese, Italy), of the Bellaria Hospital/University of Bologna (Bologna, Italy), of the Istituto Ortopedico Rizzoli (Bologna, Italy), and of Città della Salute e della Scienza/University of Turin (Turin, Italy) were retrospectively analyzed to identify cutaneous MCCs diagnosed between 1993 and 2015. The clinico-pathological information including gender, age at the time of diagnosis, tumor size and site, presence of lymph node and/or distant metastases, stage, and available clinical follow-up data were collected from hospital medical records, from general physician or referring specialist, and from local Tumor Registry. Patients were followed up for at least 36 months after surgery.

Morphological and Immunohistochemical Analysis

Tissues were fixed in buffered formalin and routinely processed to paraffin. Histological slides were stained with hematoxylin and eosin and reviewed by three pathologists with an expertise in neuroendocrine neoplasms (SA, SLR, and SU) to confirm the diagnosis and to evaluate the following morphological parameters: diameter, thickness of infiltration, mitotic count (number of mitoses per 2 mm²), angioinvasion, and margin status. In general, immunohistochemical stains for synaptophysin, chromogranin A, and cytokeratin 20 were already available because routinely performed in the diagnostic workup. The other immunohistochemical markers, including Ki67, p63, and MCPyV, were performed when missing in the original records. Immunohistochemistry was performed in an automated stainer (Benchmark XT; Ventana Medical Systems, Tucson, AZ) using 3-μm-thick sections and the antibodies listed in Table 1. Ki67 proliferative index was evaluated in one selected block and always at distance from ulceration, if present. The distribution of Ki67 labelling was rather homogeneous in cases with the highest scores (>55%), while it was heterogeneous when the percentage of positive cells was lower. In agreement with the most recent guidelines, Ki67 proliferative index in case with heterogeneous Ki67 expression was evaluated in the hot spot area (selected at low magnification) by counting the number of positive cells in at least 500 tumor cells (range 500–2000 neoplastic cells) on camera-captured printed images [4, 9].

Statistical and Survival Analysis

Summary statistics have been reported as number and percentage, mean (± standard deviation-SD) or median (standard error (SE), and corresponding 95% confidence intervals (CI)) when appropriate. Student’s t test has been performed to compare continuous variable across groups. Chi square tests were used to compare percentage thresholds across groups. All possible prognostic factors were submitted to a Cox proportional-hazard regression. All factors with a p value ≤0.05 then entered in a multivariate Cox regression, along with potential confounders. Hazard ratios (HR) and 95% CI are also indicated. Kaplan–Meier estimator was used to estimate the survival function from lifetime data including overall survival and disease-specific survival cumulative rates. Formal test for equality of survivor function was performed by log rank test. Optimal cut-point for Ki67 index was investigated using Youden’s index for the receiver operating characteristic (ROC) curve analysis. A p value < 0.05 was considered significant. All tests were two-sided. Analyses were performed.
with Stata14.2 (®2013 Stata Corp Austin, US) and SPSS 26.0 (®2019 SPSS Inc., Chicago, IL, USA).

Revision of the Literature

The PubMed database of the National Center for Biotechnology Information (NCBI) of the US National Library of Medicine was searched using the following string: Ki67 [AND] Merkel cell carcinoma or proliferation [AND] Merkel cell carcinoma. All articles written in English were included. In addition, we revised the reference lists of each paper selected in the PubMed database, with the aim of reducing the risk of missing pertinent articles. For each identified article, the following information was considered: number of cases in each series, the mean Ki67 proliferative index value, the Ki67 cut-off selected for survival analyses, and correlation of the Ki67 proliferative index with disease recurrence, overall (OS), and disease-specific (DSS) survival.

Results

Clinico-Pathological and Immunohistochemical Results

From a larger series of 100 patients, 84 cases had complete clinical information and material for immunohistochemical characterization available. The main clinico-pathologic features of the 84 patients are summarized in Table 2. Males were more frequently affected than females (p:0.02), and the average age at diagnosis was 76 years (range 42–94 years). Mean age was slightly higher among women (79 vs 74 years).

The mean diameter of MCCs was 2.49 cm (range 0.3–12), and the mean thickness of infiltration was 9.24 mm (range 0.5–21 mm). All tumors showed the classical morphological features of skin MCC including small to intermediate cells with monomorphic nuclei displaying a finely dispersed chromatin, inconspicuous nucleoli, and scant cytoplasm. Co-existent non-neuroendocrine components (including squamous cell carcinoma or basal cell carcinoma) were never observed. The mean mitotic count was 37 mitoses × 2mm² and 54 cases (64%) showed angioinvasion. MCPyV nuclear immunoreactivity was identified in 71 cases (85%) and p63 expression in 38 cases (45%). The mean Ki67 proliferative index was 51.3%, ranging between 20 and 95%.

Table 2 Main clinico-pathological features of Merkel cell carcinomas

| Gender | Men | Women |
|--------|-----|-------|
|        | 50/84 (60%) | 34/84 (40%) |

| Age (years) | Mean | Range |
|-------------|------|-------|
|             | 76   | 42–94 |

| Site | Head and neck | 31 |
| Trunk and buttock | 17 |
| Extremities (3) | 36 |
| Tumor diameter (cm) | Mean | 2.49 |
|                  | Range | 0.3–12 |
| Tumor thickness (mm) | Mean | 9.24 |
|                  | Range | 0.5–21 |
| Angioinvasion | Yes | 54/84 (64%) |
|               | No | 30/84 (36%) |
| Mitoses × 2mm² | Mean | 37 |
|                | Range | 4–180 |
| Ki67 ≥ 55% | 30/84 (36%) |
| Ki67 < 55% | 54/84 (64%) |
| Stage I | 27/84 (32%) |
| II | 23/84 (27%) |
| III | 23/84 (27%) |
| IV | 11/84 (13%) |
| p63 + | 38/84 (45%) |
| p63 – | 46/84 (55%) |
| MCPyV + | 71/84 (85%) |
| MCPyV – | 13/84 (15%) |

MCPyV Merkel cell polyomavirus
Survival Analysis

The 5-year OS and DSS were 52% and 66%, respectively (Fig. 1). The median OS and DSS for the whole series were of 62 months (SE 9.376, 95% CI 43.622–80.378) and 96 months (SE 21.371, 95% CI 54.112–137.888), respectively. Twenty-eight subjects (33% of the whole population) died of their disease (DOD).

In the whole group, the univariate analysis showed that AJCC stage (HR 1.864, 95% CI 1.295–2.682, \( p = 0.001 \)), p63 immunohistochemical expression (HR 8.304, 95% CI 3.285–20.991, \( p < 0.001 \)), absence of MCPyV immunoreactivity (HR 2.740, 95% CI 1.133–6.628, \( p = 0.025 \)), and Ki67 index (HR 1.013–1.055, \( p = 0.002 \)) were significantly associated with shorter DSS (Table 3). Early AJCC stages of disease (I and II) presented similar DSS rates. The most remarkable difference in survival analysis was observed grouping stages I and II together against grouped stages III and IV (log-rank test \( p < 0.001 \)) (Fig. 2). Fifty-four percent of patients with MCPyV-negative MCCs died of disease versus 30% of patients with MCPyV-positive MCCs (\( p = 0.019 \)). Seventy-six percent of patients with p63-positive MCCs died of disease, versus 24% of patients with p63-negative MCCs (\( p < 0.001 \)) (Fig. 3).

Since Ki67 proliferative index \( \geq 55\% \) has been demonstrated to be associated with worse prognosis in large series of digestive NECs [10, 11], we performed the Kaplan-Meier estimator analysis using the same cut-off. Youden’s index for ROC curve analysis identified 50.5% and 57.5% Ki67 values as optimal cut-points to detect DOD patients (\( J = 0.214 \)), corroborating the use of the threshold of 55%. Interestingly, when patients were classified according to outcome (alive and well, alive with disease, died of other cause, and died of disease), MCCs with Ki67 index \( \geq 55\% \) were more frequently observed in patients with progressive/persistent disease (died of disease or alive with disease) than in patients free of disease (\( p = 0.001 \)) (Fig. 4).

Table 3 Cox univariate analysis of variables in relations to the disease-specific survival

| Variable                  | HR (CI 95%) | \( p \) value |
|---------------------------|-------------|---------------|
| Age (log)                 | 1.016 (0.978–1.055) | 0.42         |
| Sex (male)                | 2.05 (0.871–4.826) | 0.1          |
| Size (cm)                 | 0.94 (0.75–1.178)  | 0.592        |
| Site (head and neck)      | 1.766 (0.821–3.798) | 0.145        |
| AJCC stage (log)          | 1.864 (1.295–2.682) | 0.001        |
| Margin status (R1)        | 0.736 (0.296–1.833) | 0.51         |
| Tumor thickness (log)     | 1.015 (0.946–1.089) | 0.676        |
| Tumor growth (infiltrative)| 1.371 (0.637–2.955) | 0.42         |
| Angioinvasion (present)   | 2.177 (0.921–5.145) | 0.076        |
| Mitosis × HPF (log)       | 0.996 (0.986–1.006) | 0.466        |
| p63 (expressed)           | 8.304 (3.285–20.991) | \(< 0.001\) |
| MCPyV (negative)          | 2.740 (1.133–6.628) | 0.025        |
| Ki67 index (log)          | 1.033 (1.013–1.055) | 0.002        |

HR, hazard ratio; MCPyV, Merkel cell polyomavirus; HPF, high power field

These four factors (stage, p63, MCPyV, Ki67) were entered into a multivariate analysis with patients’ age and gender considered as correction factors. p63 expression (HR 7.254, 95% CI 2.792–18.843, \( p < 0.001 \)) and AJCC advanced stage (HR 1.934, 95% CI 1.239–3.018, \( p = 0.004 \)) remained the only independent factors significantly affecting the DSS.

The prognostic role of the Ki67 proliferative index was also explored in the subgroup of MCPyV-positive tumors (71 cases). Similar to what observed in the analysis of the entire cohort, Ki67 proliferative index \( \geq 55\% \) was statistically associated with DSS at the univariate Cox proportional-hazard regression analysis (\( p = 0.002 \), HR 1.041, 95% CI 1.015–1.067), but it was not an independent prognostic factor at the multivariate analysis as compared to p63 and AJCC advanced stage.
Discussion

MCC of the skin is a rare neuroendocrine carcinoma with a reported 5-year overall survival (OS) ranging from 30 to 60% [12–14], and our findings are in line with this, showing a 5-year OS of 52%, worse than the 5-year DSS (66%). This probably reflects the characteristics of our cohort, where most of patients were elderly (mean age 76 years) with other co-morbidities and fatal events for unrelated causes. A similar feature was observed by Jemec et al., whose series of MCCs showed an OS worse than DSS after a mean follow-up time of 68.2 months [15]. Several different clinico-pathological factors negatively influencing patients’ survival have been proposed for cutaneous MCC and included age, male gender, clinical evidence of lymph node metastasis, depth of tumor invasion, infiltrative growth pattern, loss of RB function, lack of MCPyV immunoreactivity, and p63 expression [16–19].

More recently, promoter methylation of the immune

![Fig. 2](image-url)  
**Fig. 2** Disease-specific survival (DSS) related to AJCC tumor stage. Stages I and II presented similar DSS rates as compared to stages III and IV (a). Different DSS was observed when grouping stage I with II and compared with stage III with stage IV grouped together (b) (log-rank test p < 0.001)

![Fig. 3](image-url)  
**Fig. 3** Patients with Merkel cell carcinomas expressing MCPyV show a better survival than patients with MCPyV-negative carcinomas (a). MCPyV immunoreactivity is nuclear (b). Image (c) is an example of a MCPyV-negative Merkel cell carcinoma. Expression of p63 by neoplastic cells is associated with a worse prognosis (d). In image (e), there is an example of p63-negative Merkel cell carcinoma. Note the internal control in the basal layer of the normal epidermis. p63 is expressed in the nuclei of cancerous cells (f)
checkpoint receptor CD279 (PD-1) and intratumor lymphocyte subtypes have been suggested as additional prognostic factors [20, 21].

Ki67 proliferative index represents one of the most important biological markers routinely used as prognosticators in NENs. Its role was first demonstrated in pancreatic NETs [22, 23] and then in other digestive NETs [4] as well as in NETs of other sites (e.g., in the pituitary gland) [5, 6]. Recent data also suggest a prognostic role of Ki67 proliferative index in lung NENs and in non-epithelial NENs, like olfactory neuroblastoma [8, 24]. In addition to NETs, Ki67 proliferative index also plays a prognostic role in NECs, as observed in the digestive system; indeed, NECs with a Ki67 index > 55% show worse prognosis than NECs with Ki67 index < 55%, despite a better initial response of the former to chemotherapy [10, 11]. For all these reasons, the evaluation of Ki67 is a required parameter in the diagnostic work-up of NENs.

Despite the large available literature on the prognostic role of Ki67 index in NENs, the available data on MCC are heterogeneous, mainly due to the different methods used to assess Ki67 proliferative index and the relatively small number of cases studied in each series. Although some studies suggested an association between Ki67 index and a more aggressive clinical behavior [19, 25, 26], others did not confirm this data [15, 27–32] (Table 4). Although Ki67 is a continuous variable, the current stratification of patients is generally related to specific Ki67 cut-offs, which are able to separate patients in different prognostic categories. However, standardized method of evaluation such as that proposed by the WHO [4, 9] is mandatory. Since MCC may be considered as the cutaneous counterpart of visceral NECs and since no specific prognostic Ki67 cut-off has been identified for MCC, we decided to use the only available and efficient Ki67 threshold (55%), although it refers to digestive NECs [10, 11]. This choice was also supported by the Youden index analysis, which identified best cut-point Ki67 values at 52.5% and 57.5%. We observed an association between Ki67 proliferative index higher than 55% and tumor recurrence, in line with other published findings [27, 29, 35, 36, 39]. In addition, we demonstrated, at univariate analysis, the relationship between high Ki67 proliferative index and DSS, a finding not confirmed by previous studies (Table 4). Indeed, in three studies, only the association between Ki67 proliferative index and OS, but not DSS, was observed [19, 25, 26]. These discrepancies may be due to the different methods used to evaluate the Ki67 proliferative index and to the different cut-offs established.

Fig. 4 Kaplan-Meyer curve (a) demonstrating that patients with Merkel cell carcinomas showing a Ki67 proliferative index < 55% (b) show a better survival than patients with Merkel cell carcinomas with a Ki67 index ≥ 55% (c). Merkel cell carcinomas with Ki67 index ≥ 55% were observed more frequently in patients with disease, both died (DOD) and alive (AWD) than in patients alive free of disease (AFD) or died for other causes (DOC) (d).
for the survival analysis. Regarding the first point, we are the first to use the WHO recommendations by counting the number of positive cells in at least 500 tumor cells in hot spot areas on camera-captured printed images [4, 9]. As discussed above, the choice of 55% Ki67 cut-off was based on the analogy with digestive NECs and on the Youden index analysis. Our results on MCCs are in line with those observed in digestive NECs that showed different survivals, when separated in two groups based on Ki67 proliferative index (< 55% vs > 55%), [11].

However, although Ki67 proliferative index resulted significantly associated with prognosis at univariate analysis, together with tumor stage IV, MCPyV lack, and p63 expression [16–19], it was not an independent predictor at the multivariate analysis, where survival resulted independently influenced by p63 expression and tumor stage, only.

The prognostic role of p63 expression is in line with previous findings [19], and it may be related to its function as tumor suppressor as demonstrated in p63 knockout mice [43]. However, it is worth noting that different p63 isoforms exist and may have distinct effects on oncogenesis. Since the anti-p63 antibody used in this study does not distinguish among different isoforms, we are not able to identify the p63 isoform having the major pathogenetic role. Asioli et al. have demonstrated that TAp63a and DNp63a were the most frequently expressed isoforms (42%) in low-stage MCCs, suggesting that an early anomalous regulation of their expression might determine an aggressive phenotype [44].

In contrast to proliferation markers, a possible prognostic role of factors influencing apoptosis has been poorly investigated in MCCs. Indeed, although apoptotic cells were detected in MCCs using TUNEL, DNA ladder and immunohistochemistry for Fas (Apo-1/CD95) [45], the prognostic role of apoptotic index and of proteins and mediators involved in the apoptotic machinery (Bcl-2, p53, Surviving, and CXCR4) remains to be elucidated [30].

In conclusion, this study, which integrates original findings with literature data, is the first one analyzing the prognostic role of Ki67 proliferative index in MCC using a standardized methods of Ki67 evaluation. Nevertheless, although Ki67 proliferative index was associated with recurrent disease and shorter patients’ survival at univariate analysis, it did not prove to independently influence prognosis, which in our

---

Table 4  Review of the literature: prognostic role of Ki67 in Merkel cell carcinoma

| Reference        | Year | Number of cases | Ki67 mean value | Ki67 cut-off | Correlation with recurrence and/or MTS | Correlation with DSS |
|------------------|------|-----------------|-----------------|--------------|----------------------------------------|----------------------|
| Parrado [27]     | 1998 | 25              | 40%             | nr           | Yes                                    | No                   |
| Carson [28]      | 1998 | 20              | nr              | nr           | No^                                      | No^                  |
| Jeffery [15]     | 2000 | 13              | nr              | nr           |                                        | No                   |
| Erickson [33]    | 2003 | 39              | 36.8%           | nr           | nr                                     | nr                   |
| Acebo [34]       | 2005 | 11              | 75%             | nr           | nr                                     | nr                   |
| Fernandez-Figueras [35] | 2005 | 24              | 46.67%          | *            | Yes                                    | nr                   |
| Llombardi [29]   | 2005 | 20              | nr              | 50%          | Yes                                    | No                   |
| Kolonen [36]     | 2006 | 24              | 47%             | 35%          | Yes                                    | nr                   |
| Tucci [30]       | 2006 | 12              | nr              | #            | No                                     | No                   |
| Bethocine [37]   | 2006 | 11              | 50%             | nr           | nr                                     | nr                   |
| Pozo [38]        | 2007 | 27              | 46.97%          | nr           | nr                                     | nr                   |
| Asioli [19]      | 2007 | 47              | 50.6%           | 65%          | nr                                     | nr°                  |
| Kim [31]         | 2008 | 19              | nr              | nr           | nr                                     | No                   |
| Sihto [16]       | 2011 | 91              | nr              | nr           | nr                                     | nr                   |
| Lim [32]         | 2012 | 95              | 60% (median)    | 50%          | nr                                     | No                   |
| Henderson [25]   | 2014 | 21              | nr              | nr           | nr                                     | No°°                  |
| Vujic [39]       | 2015 | 26              | 52%             | §            | Yes                                    | nr                   |
| Iwasaki [26]     | 2015 | 28              | 54.5%           | 60%          | nr                                     | No°°°                 |
| Lezoux-Kozal [40] | 2015 | 15              | 46%             | nr           | nr                                     | nr                   |
| Orlova [41]      | 2018 | 32              | nr              | nr           | nr                                     | nr                   |
| Kitamura [42]    | 2018 | 10              | 53%             | nr           | nr                                     | nr                   |
| Present series   | 84   | 51.3%           | 55%             | Yes          |                                        | No                   |

MTS, metastases; DSS, disease-specific survival; nr, not reported; ^cases were considered positive when Ki67 > 10%; °not identified but metastases and recurrence were observed when Ki67 > 54%; *not identified but worse prognosis were observed when Ki67 > 51.46%; correlation with OS (p<0.001), but not in multivariate analysis; **correlation with OS (p<0.0597); †not identified but aggressive behavior was observed when Ki67 > 67%; ***correlation with OS (p<0.048)
relatively large series mainly depended on high tumor stage and p63 expression.

Authors' Contributions SLR, SU: study design, data collection, drafting. SA, RM, MA, MPF, FM, AM, FS, MP, AR: data collection. MB, AS: statistical analysis. All authors approved the manuscript.

Funding Information Open access funding provided by University of Lausanne.

Compliance with Ethical Standards

Conflict of Interest The authors declare that they have no conflict of interest.

Ethical Approval This study was performed according to the clinical standards of the 1975 and 1983 Declaration of Helsinki and was approved by the Ethical Committee of the ASST Sette Laghi, Varese, Italy (prot. nr: 0008465).

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Fitzgerald TL, Dennis S, Kachare SD, Vohra NA, Wong JH, Zervos EE (2015) Dramatic increase in the incidence and mortality from Merkel cell carcinoma in the United States. Am Surg 81:802-806
2. Amaral T, Leiter U, Garbe C (2017) Merkel cell carcinoma: epidermolysis, pathogenesis, diagnosis and therapy. Rev Endocr Metab Disord 18:517-532
3. Moshiri AS, Doumani R, Yelistratova L, et al (2017) Polyomavirus-negative Merkel cell carcinoma: a more aggressive subtype based on analysis of 282 cases using multimodal tumor virus detection. J Invest Dermatol 137:819-827
4. Klöppel G, La Rosa S (2018) Ki67 labeling index: assessment and prognostic role in gastrointestinal neuroendocrine neoplasms. Virchows Arch 472:341-349. Erratum in: Virchows Arch. 2017 Dec 26
5. Alshaikh OM, Asa SL, Mete O, Ezzat S (2019) An institutional experience of tumor progression to putitary carcinoma in a 15-year cohort of 1055 consecutive putitary neuroendocrine tumors. Endocr Pathol 30:118-127
6. Petry C, Poli JHZ, de Azevedo Dossin I, Rech CGSL, Pereira Lima JFS, Ferreira NP, da Costa Oliveira M (2019) Evaluation of the potential of the Ki67 index to predict tumor evolution in patients with putitary adenoma. Int J Clin Exp Pathol 12:320-326
7. Silva-Figueiroa AM, Bassett R Jr, Christakis I, Moreno P, Clarke CN, Busaidy NL, Grubbs EG, Lee JE, Perrier ND, Williams MD (2019) Using a novel diagnostic nomogram to differentiate malignant from benign parathyroid neoplasms. Endocr Pathol 30:285-296
8. Rindi G, Klersy C, Inzani F et al (2013) Grading the neuroendocrine tumors of the lung: an evidence-based proposal. Endocr Relat Cancer 21:1-16
9. Klöppel G, Couvelard A, Hruban RH, Klimstra DS, Komminoth P, Osamura YR, Perren A, Rindi G (2017) Neoplasms of the neuroendocrine pancreas: introduction. In: Lloyd RV, Osamura RY, Klöppel G, Rosai J (eds) WHO classification of tumours of endocrine organs, 4th edn. IARC, Lyon, pp 211-214
10. Sorbye H, Welin S, Langer SW, et al (2013) Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): the NORDIC NEC study. Ann Oncol 24:152-160
11. Milione M, Maisonneuve P, Spada F, Pellegrinelli A, Spaggiari P, Albarello L, Pisa E, Barberis M, Yanoli A, Buzzonni R, Pusceddu S, Concà L, Sessa F, Solcia E, Capella C, Fazio N, La Rosa S (2017) The clinicopathologic heterogeneity of grade 3 gastroenteropancreatic neuroendocrine neoplasms: morphological differentiation and proliferation identify different prognostic categories. Neuroendocrinology 104:85-93
12. Medina-Franco H, Uriat MM, Fiveash J, Heslin MJ, Bland KI, Beeken SW (2001) Multimodality treatment of Merkel cell carcinoma: case series and literature review of 1024 cases. Ann Surg Oncol 8:204-208
13. Lemos BD, Storer BE, Iyer JG et al (2010) Pathologic nodal evaluation improves prognostic accuracy in Merkel cell carcinoma: analysis of 5823 cases as the basis of the first consensus staging system. J Am Acad Dermatol 63:751-761
14. van Veenendaal LM, van Akkooi ACJ, Verhoef CJ, Grünewald H, Klopp WMC, Valk GD, Tesselaar MET (2018) Merkel cell carcinoma: Clinical outcome and prognostic factors in 351 patients. J Surg Oncol 117:1768-1775
15. Jemec B, Chana J, Grover R, Grubbelaar AO (2000) The Merkel cell carcinoma: survival and oncogene markers. J Eur Acad Dermatol Venereol 14:400-404
16. Shto H, Kukko H, Koljonen V, Sankila R, Böhlöng T, Joensu H (2011) Merkel cell polyomavirus infection, large T antigen, retinoblastoma protein and outcome in Merkel cell carcinoma. Clin Cancer Res 17:4806-4813
17. Andea AA, Coti DG, Amin B, Busam KJ (2008) Merkel cell carcinoma: histologic features and prognosis. Cancer 113:2549-2558
18. Fields RC, Busam KJ, Chou JF, Panageas KS, Pulitzer MP, Allen PJ, Kraus DH, Brady MS, Coti DG (2011) Five hundred patients with Merkel cell carcinoma evaluated at a single institution. Ann Surg 254:465-473
19. Asili S, Righi A, Volante M, Eusebi V, Bussolati G (2007) p63-proliferating-cell nuclear antigen and progesterone receptor protein as a new prognostic marker in Merkel cell carcinoma. Cancer 110:640-647
20. Ricci C, Morandi L, Righi A, Gibertoni D, Maletta F, Ambrosi F, Agostinelli C, Uccella S, Asili S, Sessa F, Pellilii M, Maragliano R, La Rosa S, Papotti MG, Asili S (2019) PD-1 (PDCD1) promoter methylation in Merkel cell carcinoma: prognostic relevance and relationship with clinico-pathological parameters. Mod Pathol 32:1359-1372
21. Ricci C, Righi A, Ambrosi F, Gibertoni D, Maletta F, Uccella S, Sessa F, Asili S, Pellilii M, Maragliano R, La Rosa S, Papotti MG, Asili S (2020) Prognostic impact of MCPyV and TIL subtyping in Merkel cell carcinoma: evidence from a large European cohort of 95 patients. Endocr Pathol 31:21-32
22. Pelosi G, Bresaola E, Bogina G, Pasini F, Rodella S, Castelli P, Iacono C, Serio G, Zamboni G (1996) Endocrine tumors of the pituitary adenoma. Int J Clin Exp Pathol 12:320-326
immunostaining, mitotic index, and other clinicopathologic variables. Hum Pathol 27:1124-1134
23. La Rosa S, Sessa F, Capella C, Riva C, Leone BE, Klersy C, Rindi G, Solcia E (1996) Prognostic criteria in nonfunctioning pancreatic endocrine tumours. Virchows Arch 429:323-333
24. Turri-Zanoni M, Maraglino R, Battaglia P, Giovannardi M, Antognoni P, Lombardi D, Morassi ML, Pasquini E, Tarchini P, Ascoli S, Foschini MP, Sessa F, Nicolai P, Castelnuovo P, La Rosa S (2017) The clinicopathological spectrum of olfactory neuroblastoma and sinonasal neuroendocrine neoplasms: Refinements in diagnostic criteria and impact of multimodal treatments on survival. Oral Oncol 74:21-29
25. Henderson SA, Tetzlaff MT, Pattanaprichakul P, Fox P, Torres-Cabala CA, Bassett RL, Prieto VG, Richards HW, Curry JL (2014) Detection of mitotic figures and G2+ tumor nuclei with histone markers correlates with worse overall survival in patients with Merkel cell carcinoma. J Cutan Pathol 41:846-852
26. Iwasaki T, Matsushita M, Nonaka D, Kato M, Nagata K, Murakami I, Hayashi K (2015) Phosphohistone-H3 (PHH3) is prognostic relevant in Merkel cell carcinomas but Merkel cell polyomavirus is a more powerful prognostic factor than AJCC clinical stage, PHH3, Ki-67 or mitotic indices. Pathol Int 65:404-409
27. Parrado C, Bjömhagen V, Eusebi V, Falkmer UG, Höög A, Garcia-Caballero T, Pérez de Vargas I, Falkmer S (1998) Prognosticating tools in primary neuroendocrine (Merkel-cell) carcinomas of the skin: histopathological subdivision, DNA cytometry, cell proliferation analyses (Ki-67-immunoreactivity) and NCAM immunohistochemistry. A clinicopathological study in 25 patients. Pathol Res Pract 194:11-23
28. Carson HJ, Reddy V, Taxy JB (1998) Proliferation markers and prognosis in Merkel cell carcinoma. J Cutan Pathol 25:16-19
29. Llombart B, Monteagudo C, López-Guerrero JA, Carda C, Jordà E, Sammartín O, Almenar S, Molina I, Martín JM, Llombart-Bosch A (2005) Clinicopathological and immunohistochemical analysis of 20 cases of Merkel cell carcinoma in search of prognostic markers. Histopathology 46:622-634
30. Tucci MG, Lucarini G, Giangiacomi M, Zizzi A, Criante P, Ricotti G, Biagini G (2006) Immunohistochemical study of apoptosis markers and involvement of chemokine CXCR4 in skin Merkel cell carcinoma. J Eur Acad Dermatol Venereol 20:1220-1225
31. Kim J, McNiff JM (2008) Nuclear expression of survivin portends a poor prognosis in Merkel cell carcinoma. Mod Pathol 21:764-769
32. Lim CS, Whalley D, Haydu LE, Murali R, Tippett J, Thompson JF, Hruby Gi, Scolley RA (2012) Increasing tumor thickness is associated with recurrence and poorer survival in patients with Merkel cell carcinoma. Ann Surg Oncol 19:3325-3334
33. Erickson LA, Papotti M, Volante M, Jin L, Lewis JE, Lloyd RV (2003) Merkel cell carcinomas: expression of S-phase kinase-associated protein 2 (Skp2), p27, and proliferation markers. Endocr Pathol 14:221-229
34. Acebo E, Vidaurrazaga N, Varas C, Burgos-Bretones JJ, Díaz-Pérez JL (2005) Merkel cell carcinoma: a clinicopathological study of 11 cases. J Eur Acad Dermatol Venereol 19:546-551
35. Fernández-Figuera MT, Puig L, Musulen E, Gilaberte M, Fernández C, Lerma E, Ariza A (2005) Prognostic significance of p27Kip1, p45Skp2 and Ki67 expression profiles in Merkel cell carcinoma, extracutaneous small cell carcinoma, and cutaneous squamous cell carcinoma. Histopathology 46:614-621
36. Koljonen V, Tukiainen E, Haglund C, Böhling T (2006) Proliferative activity detected by Ki67 correlates with poor outcome in Merkel cell carcinoma. Histopathology 49:551-553
37. Belhocine T, Pierard GE, Frühling J, Letesson G, Bolle S, Hustinx R, Dargent JL, Flamen P, Rigo P (2006) Clinical added-value of 18FDG PET in neuroendocrine-merkel cell carcinoma. Oncoi Rep 16:347-352
38. Pozo L, Sanchez-Carrillo J, Martinez A, Blanes A, Diaz-Cano SJ (2007) Differential kinetic features by tumour topography in cutaneous small-cell neuroendocrine (Merkel cell) carcinomas. J Eur Acad Dermatol Venereol 21:1220-1228
39. Vujic I, Marker M, Posch C, Mühlechner D, Monshi B, Breier F, Steinreiter A, Ortiz-Urda S, Rappersberger K (2015) Merkel cell carcinoma: mitoses, expression of Ki-67 and bel-2 correlate with disease progression. J Eur Acad Dermatol Venereol 29:542-548
40. Leroux-Kozal V, Lévéque N, Brodard V, Lesage C, Dudez O, Makeieff M, Kanagaratnam L, Diebold MD (2015) Merkel cell carcinoma: histopathologic and prognostic features according to the immunohistochemical expression of Merkel cell polyomavirus large T antigen correlated with viral load. Hum Pathol 46:443-453
41. Orlova KV, Delektorskaya VV, Vishnevskaya VV, Kondratieva TT, Orel NF, Markovich AA, Demidov LV, Subramanian S (2018) Somatostatin receptor type 2 expression in Merkel cell carcinoma as a prognostic factor. J Eur Acad Dermatol Venereol 32:e236-e237
42. Kitamura S, Yanagi T, Inamura-Takashima Y, Imafuku K, Hata H, Uehara J, Ishida Y, Otsuka A, Hirata K, Shimizu H (2018) Fluorodeoxyglucose uptake in positron emission tomography-computer tomography and tumour volume, cytological activity as assessed with Ki-67 and GLUT-1 staining in 10 cases of Merkel cell carcinoma. J Eur Acad Dermatol Venereol 32:e285-e287
43. Flores ER, Sengupta S, Miller JB, Newman J, Bronson R, Crowley D, Yang A, McKeon F, Jacks T (2005) Tumor predisposition in mice mutant for p63 and p73: evidence for broader tumor suppressor functions for the p53 family. Cancer Cell 7:363-373
44. Asioli S, Righi A, de Biase D, et al. (2011) Expression of p63 is the most powerful prognostic factor in Merkel cell carcinoma. Histopathology 59:345-354
45. Mori Y, Hashimoto K, Tanaka K, Cui CY, Mehregan DR, Stiff MA (2015) Phosphohistone-H3 (PHH3) is a marker of higher grade tumor in Merkel cell carcinoma. Oral Oncol 74:21-29
Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.